2025 Annual Meeting Presentation Material

Iperion Limited
Annual Meeting
26 September 2025

Agenda
•Welcome and Introductions
•Formalities
•Presentation to Shareholders
•Q&A Discussion
•Resolutions
•Appendix:AdditionalinformationonPathoglaze

Formalities
•Attendance of the virtual meeting has been left open for all
interested to be able to attend.
•The meeting is recorded.
•To ensure that voting is accounted for correctly, all votes will
be required to be submitted electronically. For shareholders
who have not voted yet via MUFG, but still wish to do so after
the meeting, please forward your completed voting form to
john.cilliers@iperion.co.nzby no later than 4pm today.
(contact John if you need a form)

Review of the year ended 31 March 2025
•Decrease in interest income as result of
lower bank interest rates and deposit
value
•Received a $250,000 discount on fixed
Outsource Plant expense. 2024
includes establishment cost of $100k.
•Admin expenses lower in 2025 mainly
in stock exchange fees and marketing
activities.
•Impairment expense is on trademark
intangibles. Expected to be reversed
once the value of sales support the
intangibles valuation.
•There were no changes in the number
of shares on issue.
2025
$
2024
$
Interest income20,38241,396
Outsource
Manufacturing Plant
150,000500,000
Administrative expenses317,781354,372
Impairment expense8,2849,283
Net loss455,683822,259
Net assets348,398804,081
Cash and Term deposits425,341866,481

Progress and current activities
▪Continued marketing activities and presentations at events mainly in
South East Asia.
▪Ongoing product trials with potential customers across South East Asia,
Europe and the Middle East.
▪Pathoglaze
®
trademark registrationscompleted in accordance with the
Madrid protocol
▪Initiatives to conserve cash reserves:
▪Fixed annual fee on Pilot Outsource Facility for current financial year is fully
discounted by vendor as facility is being supported by research grants
obtained.
▪Directors have agreed have agreed to defer payment on 50% of management
and director fees starting from November 2025 until achievement of sufficient
sales to achievepositivecashflow.

Pathoglazeis a durable, high potency, anti-
microbial product capable of being
incorporated into raw materials for other
products at the point of manufacture.
For example it can be incorporated in plastics
masterbatch powders prior to product
moulding or it can be applied to existing
products as a thin film coating.

•Good progress being made in
development of Pathoglaze infused
polymer jute bags used for shipping
cocoa and coffee beans.
•These bags reduce losses that result
from microbial contamination during
shipping and transport.
•Likely 1
st
sales will be with a
multinational chocolate manufacturer.

Questions

Resolution 1
Bruce Dunlop retires by rotation in accordance with the Company’s constitution and NZX
Listing Rule 2.7.1. . Being eligible, Bruce offers himself for re-election. The Board considers
Bruce to be an Independent Director. Accordingly, the shareholders of the Company are
requested to consider and, if thought fit, pass the following resolution as an Ordinary
Resolution.
Ordinary Resolution: That Bruce Dunlop, who retires in accordance with NZX Listing Rule
2.7.1, and being eligible for re-election, be re-elected as a director of IPR.
ForOpenAgainst
% of Issued
Capital
Abstain
Votes
406,663,155505,000079.08%
0
Holders
570
Percentage
99.88%0.12%0.00%
Proxies:

Resolution 2
Chang Ku EE retires by rotation in accordance with the Company’s constitution and NZX
Listing Rule 2.7.1. Being eligible, Chang Ku EE offers himself for re-election. The Board does
not consider Mr EE to be an Independent Director. Accordingly, the shareholders of the
Company are requested to consider and, if thought fit, pass the following resolution as an
Ordinary Resolution.
Ordinary Resolution: That Chang Ku EE, who retires in accordance with NZX Listing Rule
2.7.1, and being eligible for re-election, be re-elected as a director of IPR.
ForOpenAgainst
% of Issued
Capital
Abstain
Votes
406,663,155505,000079.08%
0
Holders
570
Percentage
99.88%0.12%0.00%
Proxies:

Resolution 3
BDO is automatically reappointed at the annual meeting as the auditor of the Company
under section 207T of the Companies Act. This resolution authorises the Board to fix the
fees and expenses of the auditor.
Ordinary Resolution: That the Board is authorised to fix BDO Auckland’s fees and
expenses as the auditor of IPR.
ForOpenAgainst
% of Issued
Capital
Abstain
Votes
406,663,155505,000079.08%
0
Holders
570
Percentage
99.88%0.12%0.00%
Proxies:

Thank you

✓PATHOGLAZE® Hyperion is a high-potency zinc-based antimicrobial additive.
✓Having a core shell- nanopillar morphological structure.
✓It can kill, reduce and prevent the growth of harmful microorganism (e.g.: bacteria,
virus, fungi, algae).
✓Having an antimicrobial activity up to 99.9 % (test method: ISO22196).
✓Can be seamlessly incorporated in a wide range of end-use products during
the manufacturing process without interfering with the actual manufacturing
setup.
HYPERION Additive
– greyish powder
Fine Powder (Additives)

UNIQUE MECHANISM
Does not rely on external
stimulus light energy to
generate ROS.
SAFETY
Safe to be used as additive in
food packaging polymers.
*Tested in compliance with
USFDAand EU regulation.
EFFICACY
99.9 % effective against
microorganisms, even
at low use levels.
STABILITY
It has thermal resistance
up to 410 °C and is
insoluble in water.
FLEXIBILITY
Seamless incorporation
into a wide range of
applications.
Key Features
Additives
PATHOGLAZE

PLASTICS AND POLYMERS
(Food-grade and non food-grade)
List of polymers compatible with PATHOGLAZE:
i.Commodity thermoplastics (i.e.: PE, PS)
ii.Engineering thermoplastics (i.e.: PC, ABS, PC/ABS,
PA)
iii.Thermosets (i.e.: epoxy)
iv.Synthetic rubber (i.e.: NBR and EPDM)
PAINTS AND COATINGS
By Applications
Area of Application
PATHOGLAZE®

✓Our PATHOGLAZE® additives are compatible with almost all plastics and
polymer materials (i.e.: trial for PP, PC and ABS).
✓With 0.5% of PATHOGLAZE loading = 99.9% of antimicrobial activity
(ISO22196)
✓Seamlessly compound in polymer using the existing process
✓Embedded within the polymer compound itself, delivering continuous
protection against microbes without affecting gloss or matte surfaces, color,
durability, and properties.
PP compound with 0.5% of
PATHOGLAZE
In-polymer Food Contact Test according to
- US FDA 21 CFR 177.1520
PASS
Migration Test according to Commission Regulation (EU)
- EU 10/2011 Article 3 of European Regulation
1935/2004*
PASS
Polymer compound

P o t e n t i a l
P A T H O G L A Z E
A P P L I C A T I O N
Cutting boards, wall coverings, appliances,
toilet seats, flooring, mattresses
Housewares:
PVC blinds, car interiors, packaging, signs,
electronics, seating
Commercials:
yoga mats, footwear, duffle bags,
sports equipment
Fitness:
flooring, vinyl siding, windows, insulation,
piping, roofing membranes
Construction materials:
business supplies, medical devices, seating,
countertops, storage
Healthcare:

i.Prevents the growth of bacteria and fungi on the surface.
ii.Reduces bacteria in the surrounding area, and reduces the spread of infection.
iii.Prolongs food shelf life.
iv.Promotes product reusability and recyclability.
Antimicrobial Packaging (primary & secondary)

✓Thin film is a layer of material with a thickness ranging from a
nanometer to micrometer on the surface of a substrate.
✓Harnessing the potential of zinc, PATHOGLAZE thin film is a
zinc-based thin-film coating.
✓PATHOGLAZE® thin film series is particularly targeted for
coating on non-porous surfaces i.e.; glass windows, solar
panels, touch-sensitive displays, etc. where transparency
coating is a key consideration.
Thin Film